Last reviewed · How we verify
The ticagrelor
Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.
Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | The ticagrelor |
|---|---|
| Sponsor | Sichuan Provincial People's Hospital |
| Drug class | P2Y12 receptor inhibitor |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It achieves this by selectively and reversibly binding to the P2Y12 receptor on platelet surface, thus inhibiting adenosine diphosphate (ADP)-induced platelet activation and aggregation. This action results in a reduction of platelet aggregation and subsequent thrombus formation.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Dyspnea
- Headache
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. (PHASE1)
- Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers (PHASE1)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The ticagrelor CI brief — competitive landscape report
- The ticagrelor updates RSS · CI watch RSS
- Sichuan Provincial People's Hospital portfolio CI